"last I was aware, the CRL for GVHD required a new trial"The issue with that comment is that the information that you have seems to be about 16 months old.
I suggest if you don't trust what people have been saying here, go through the numerous MSB announcements since the CRL.
In short, as far as the market is aware the only thing outstanding is potency assays which the FDA fda havesaid are reasonable. I believe a resubmission is either prepared or being prepared.
Ann: S&P DJI Announces March 2022 Quarterly Rebalance, page-64
-
- There are more pages in this discussion • 33 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.31 |
Change
0.040(3.16%) |
Mkt cap ! $1.490B | |||
| Open | High | Low | Value | Volume |
| $1.28 | $1.32 | $1.26 | $3.433M | 2.652M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 39558 | $1.30 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.31 | 21776 | 3 |
View Market Depth
| Last trade - 16.10pm 28/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |